Adalimumab for Ocular Inflammation

Khayyam Durrani, John H. Kempen, Gui shuang Ying, R. Oktay Kacmaz, Pichaporn Artornsombudh, James T. Rosenbaum, Eric B. Suhler, Jennifer Thorne, Douglas Jabs, Grace A. Levy-Clarke, Robert B. Nussenblatt, C. Stephen Foster, Research Group SITE Research Group

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalOcular Immunology and Inflammation
DOIs
StateAccepted/In press - Mar 21 2016

Fingerprint

Inflammation
Eye Diseases
Visual Acuity
Scleritis
Anterior Uveitis
Prednisone
Adalimumab
Adrenal Cortex Hormones
Therapeutics

Keywords

  • Adalimumab
  • Humira
  • ocular inflammatory disease
  • scleritis
  • TNF-α antibody
  • uveitis

ASJC Scopus subject areas

  • Ophthalmology
  • Immunology and Allergy

Cite this

Durrani, K., Kempen, J. H., Ying, G. S., Kacmaz, R. O., Artornsombudh, P., Rosenbaum, J. T., ... SITE Research Group, R. G. (Accepted/In press). Adalimumab for Ocular Inflammation. Ocular Immunology and Inflammation, 1-8. https://doi.org/10.3109/09273948.2015.1134581

Adalimumab for Ocular Inflammation. / Durrani, Khayyam; Kempen, John H.; Ying, Gui shuang; Kacmaz, R. Oktay; Artornsombudh, Pichaporn; Rosenbaum, James T.; Suhler, Eric B.; Thorne, Jennifer; Jabs, Douglas; Levy-Clarke, Grace A.; Nussenblatt, Robert B.; Foster, C. Stephen; SITE Research Group, Research Group.

In: Ocular Immunology and Inflammation, 21.03.2016, p. 1-8.

Research output: Contribution to journalArticle

Durrani, K, Kempen, JH, Ying, GS, Kacmaz, RO, Artornsombudh, P, Rosenbaum, JT, Suhler, EB, Thorne, J, Jabs, D, Levy-Clarke, GA, Nussenblatt, RB, Foster, CS & SITE Research Group, RG 2016, 'Adalimumab for Ocular Inflammation', Ocular Immunology and Inflammation, pp. 1-8. https://doi.org/10.3109/09273948.2015.1134581
Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombudh P, Rosenbaum JT et al. Adalimumab for Ocular Inflammation. Ocular Immunology and Inflammation. 2016 Mar 21;1-8. https://doi.org/10.3109/09273948.2015.1134581
Durrani, Khayyam ; Kempen, John H. ; Ying, Gui shuang ; Kacmaz, R. Oktay ; Artornsombudh, Pichaporn ; Rosenbaum, James T. ; Suhler, Eric B. ; Thorne, Jennifer ; Jabs, Douglas ; Levy-Clarke, Grace A. ; Nussenblatt, Robert B. ; Foster, C. Stephen ; SITE Research Group, Research Group. / Adalimumab for Ocular Inflammation. In: Ocular Immunology and Inflammation. 2016 ; pp. 1-8.
@article{0215808f4409497fbc372a3298628ebc,
title = "Adalimumab for Ocular Inflammation",
abstract = "Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47{\%}), and scleritis, occurring in 9 patients (28{\%}). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47{\%}) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50{\%}). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.",
keywords = "Adalimumab, Humira, ocular inflammatory disease, scleritis, TNF-α antibody, uveitis",
author = "Khayyam Durrani and Kempen, {John H.} and Ying, {Gui shuang} and Kacmaz, {R. Oktay} and Pichaporn Artornsombudh and Rosenbaum, {James T.} and Suhler, {Eric B.} and Jennifer Thorne and Douglas Jabs and Levy-Clarke, {Grace A.} and Nussenblatt, {Robert B.} and Foster, {C. Stephen} and {SITE Research Group}, {Research Group}",
year = "2016",
month = "3",
day = "21",
doi = "10.3109/09273948.2015.1134581",
language = "English (US)",
pages = "1--8",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Adalimumab for Ocular Inflammation

AU - Durrani, Khayyam

AU - Kempen, John H.

AU - Ying, Gui shuang

AU - Kacmaz, R. Oktay

AU - Artornsombudh, Pichaporn

AU - Rosenbaum, James T.

AU - Suhler, Eric B.

AU - Thorne, Jennifer

AU - Jabs, Douglas

AU - Levy-Clarke, Grace A.

AU - Nussenblatt, Robert B.

AU - Foster, C. Stephen

AU - SITE Research Group, Research Group

PY - 2016/3/21

Y1 - 2016/3/21

N2 - Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.

AB - Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.

KW - Adalimumab

KW - Humira

KW - ocular inflammatory disease

KW - scleritis

KW - TNF-α antibody

KW - uveitis

UR - http://www.scopus.com/inward/record.url?scp=84961390336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961390336&partnerID=8YFLogxK

U2 - 10.3109/09273948.2015.1134581

DO - 10.3109/09273948.2015.1134581

M3 - Article

C2 - 27003323

AN - SCOPUS:84961390336

SP - 1

EP - 8

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

ER -